{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:41:40Z","timestamp":1778884900152,"version":"3.51.4"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T00:00:00Z","timestamp":1502841600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI11\/03026"],"award-info":[{"award-number":["PI11\/03026"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00665"],"award-info":[{"award-number":["PI15\/00665"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/00566"],"award-info":[{"award-number":["PI14\/00566"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12035-017-0705-1","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T23:52:22Z","timestamp":1502841142000},"page":"5047-5058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Inhibition of \u03b3-Secretase Leads to an Increase in Presenilin-1"],"prefix":"10.1007","volume":"55","author":[{"given":"Aitana","family":"Sogorb-Esteve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Salud","family":"Garc\u00eda-Ayll\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Llansola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Felipo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-320X","authenticated-orcid":false,"given":"Javier","family":"S\u00e1ez-Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,16]]},"reference":[{"key":"705_CR1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, De Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer\u2019s disease. Lancet 388:505\u2013517","journal-title":"Lancet"},{"key":"705_CR2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297:353\u2013356","journal-title":"Science"},{"key":"705_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R et al (2014) Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Intern Med 275:251\u2013283","journal-title":"J Intern Med"},{"key":"705_CR4","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.neurobiolaging.2009.06.002","volume":"32","author":"E Portelius","year":"2011","unstructured":"Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R et al (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32:1090\u20131098","journal-title":"Neurobiol Aging"},{"key":"705_CR5","doi-asserted-by":"crossref","first-page":"a006270","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"C Haass","year":"2012","unstructured":"Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2:a006270","journal-title":"Cold Spring Harb Perspect Med"},{"key":"705_CR6","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"R Vassar","year":"2009","unstructured":"Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer\u2019s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29:12787\u201312794","journal-title":"J Neurosci"},{"key":"705_CR7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000095267","volume":"3","author":"C Kaether","year":"2006","unstructured":"Kaether C, Haass C, Steiner H (2006) Assembly, trafficking and function of gamma-secretase. Neurodegener Dis 3:275\u2013283","journal-title":"Neurodegener Dis"},{"key":"705_CR8","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Ch\u00e1vez-Guti\u00e9rrez","year":"2012","unstructured":"Ch\u00e1vez-Guti\u00e9rrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M et al (2012) The mechanism of \u03b3-secretase dysfunction in familial Alzheimer disease. EMBO J 31:2261\u20132274","journal-title":"EMBO J"},{"key":"705_CR9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00126839-200607020-00003","volume":"7","author":"DM Barten","year":"2006","unstructured":"Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF (2006) Gamma-secretase inhibitors for Alzheimer\u2019s disease: balancing efficacy and toxicity. Drugs R&D 7:87\u201397","journal-title":"Drugs R&D"},{"key":"705_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jcpt.12112","volume":"39","author":"JA Mikulca","year":"2014","unstructured":"Mikulca JA, Nguyen V, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA et al (2014) Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther 39:25\u201337","journal-title":"J Clin Pharm Ther"},{"key":"705_CR11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/alzrt244","volume":"6","author":"JH Toyn","year":"2014","unstructured":"Toyn JH, Ahlijanian MK (2014) Interpreting Alzheimer\u2019s disease clinical trials in light of the effects on amyloid-\u03b2. Alzheimers Res Ther 6:14","journal-title":"Alzheimers Res Ther"},{"key":"705_CR12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2202-14-44","volume":"14","author":"S Sivilia","year":"2013","unstructured":"Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA, Mangano C et al (2013) Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci 14:44","journal-title":"BMC Neurosci"},{"key":"705_CR13","doi-asserted-by":"crossref","unstructured":"Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M et al (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126\u2013132","DOI":"10.1097\/01.wnf.0000167360.27670.29"},{"key":"705_CR14","doi-asserted-by":"crossref","unstructured":"Lanz TA, Hosley JD, Adams WJ, Merchant KM (2004) Studies of A\u03b2 pharmacodynamics in the brain, cerebrospinal fluid, and plasma\u00a0in young (plaque-free) Tg2576 mice using the \u03b3-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide (LY-411575). J Pharmacol Exp Ther 309:49\u201355","DOI":"10.1124\/jpet.103.060715"},{"key":"705_CR15","doi-asserted-by":"crossref","unstructured":"Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA et al (2006) Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319:924\u2013933","DOI":"10.1124\/jpet.106.110700"},{"key":"705_CR16","doi-asserted-by":"crossref","unstructured":"S\u00e4emann MD, B\u00f6hmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C et al (2000) Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 14:2380\u20132382","DOI":"10.1096\/fj.00-0359fje"},{"key":"705_CR17","doi-asserted-by":"crossref","unstructured":"Tanaka A, Hase S, Miyazawa T, Takeuchi K (2002) Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 300:754\u2013761","DOI":"10.1124\/jpet.300.3.754"},{"key":"705_CR18","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ayll\u00f3n MS, Silveyra MX, Andreasen N, Brimijoin S, Blennow K, S\u00e1ez-Valero J (2007) Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer\u2019s disease. J Neurochem 101:1701\u20131711","DOI":"10.1111\/j.1471-4159.2007.04461.x"},{"key":"705_CR19","doi-asserted-by":"crossref","unstructured":"Xu L, Kappler CS, Mani SK, Shepherd NR, Renaud L, Snider P et al (2009) Chronic administration of KB-R7943 induces up-regulation of cardiac NCX1. J Biol Chem 284:27265\u201327272","DOI":"10.1074\/jbc.M109.022855"},{"key":"705_CR20","doi-asserted-by":"crossref","unstructured":"Serf\u0151z\u0151 Z, Lontay B, Kukor Z, Erd\u0151di F (2012) Chronic inhibition of nitric oxide synthase activity by N(G)-nitro-L-arginine induces nitric oxide synthase expression in the developing rat cerebellum. Neurochem Int 60:605\u2013615","DOI":"10.1016\/j.neuint.2012.02.019"},{"key":"705_CR21","doi-asserted-by":"crossref","unstructured":"Campanari ML, Garc\u00eda-Ayll\u00f3n MS, Belbin O, Galcer\u00e1n J, Lle\u00f3 A, S\u00e1ez-Valero J (2014) Acetylcholinesterase modulates presenilin-1 levels and \u03b3-secretase activity. J Alzheimers Dis 41:911\u2013924","DOI":"10.3233\/JAD-140426"},{"key":"705_CR22","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Valero J, de Gracia JA, Lockridge O (2005) Intraperitoneal administration of 340 kDa human plasma butyrylcholinesterase increases the level of the enzyme in the cerebrospinal fluid of rats. Neurosci Lett 383:93\u201398","DOI":"10.1016\/j.neulet.2005.03.045"},{"key":"705_CR23","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Valero J, Tornel PL, Mu\u00f1oz-Delgado E, Vidal CJ (1993) Amphiphilic and hydrophilic forms of acetyl- and butyrylcholinesterase in human brain. J Neurosci Res 35:678\u2013689","DOI":"10.1002\/jnr.490350610"},{"key":"705_CR24","doi-asserted-by":"crossref","unstructured":"Evin G, Sharples RA, Weidemann A, Reinhard FB, Carbone V, Culvenor JG et al (2001) Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer\u2019s disease. Biochemistry 40:8359\u20138368","DOI":"10.1021\/bi002770t"},{"key":"705_CR25","doi-asserted-by":"crossref","unstructured":"Basavarajappa BS, Subbanna S (2014) CB1 receptor-mediated signaling underlies the\u00a0hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice\/K2 preparations. Hippocampus 24:178\u2013188","DOI":"10.1002\/hipo.22213"},{"key":"705_CR26","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ayll\u00f3n MS, Cauli O, Silveyra MX, Rodrigo R, Candela A, Compa\u00f1 A et al (2008) Brain cholinergic impairment in liver failure. Brain 131:2946\u20132956","DOI":"10.1093\/brain\/awn209"},{"key":"705_CR27","doi-asserted-by":"crossref","unstructured":"Goldstein LB, Davis JN (1990) Beam-walking in rats: studies towards developing an animal model of functional recovery after brain injury. J Neurosci Methods 31:101\u2013107","DOI":"10.1016\/0165-0270(90)90154-8"},{"key":"705_CR28","doi-asserted-by":"crossref","unstructured":"H\u00e5nell A, Marklund N (2014) Structured evaluation of rodent behavioral tests used in drug discovery research. Front Behav Neurosci 8:252","DOI":"10.3389\/fnbeh.2014.00252"},{"key":"705_CR29","doi-asserted-by":"crossref","unstructured":"Gonzalez-Usano A, Cauli O, Agusti A, Felipo V (2014) Pregnenolone sulphate restores the glutamate-nitric oxide-cGMP pathway and extracellular GABA in cerebellum and learning and motor coordination in hyperammonemic rats. ACS Chem Neurosci 5:100\u2013105","DOI":"10.1021\/cn400168y"},{"key":"705_CR30","doi-asserted-by":"crossref","unstructured":"Dovey HF, John V, Anderson JP, Chen LZ, de Saint AP, Fang LY et al (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76:173\u2013181","DOI":"10.1046\/j.1471-4159.2001.00012.x"},{"key":"705_CR31","doi-asserted-by":"crossref","unstructured":"Balmaceda V, Cuchillo-Ib\u00e1\u00f1ez I, Pujadas L, Garc\u00eda-Ayll\u00f3n MS, Saura CA, Nimpf J et al (2014) ApoER2 processing by presenilin-1 modulates reelin expression. FASEB J 28:1543\u20131554","DOI":"10.1096\/fj.13-239350"},{"key":"705_CR32","doi-asserted-by":"crossref","unstructured":"Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G et al (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17:181\u2013190","DOI":"10.1016\/S0896-6273(00)80291-3"},{"key":"705_CR33","doi-asserted-by":"crossref","unstructured":"Podlisny MB, Citron M, Amarante P, Sherrington R, Xia W, Zhang J et al (1997) Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol Dis 3:325\u2013337","DOI":"10.1006\/nbdi.1997.0129"},{"key":"705_CR34","doi-asserted-by":"crossref","unstructured":"Tong G, Castaneda L, Wang JS, Sverdlov O, Huang SP, Slemmon R et al (2012) Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral \u03b3-secretase inhibitor BMS-708163 (avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther 34:654\u2013667","DOI":"10.1016\/j.clinthera.2012.01.022"},{"key":"705_CR35","doi-asserted-by":"crossref","unstructured":"Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW et al (2012) Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430\u20131440","DOI":"10.1001\/archneurol.2012.2194"},{"key":"705_CR36","doi-asserted-by":"crossref","unstructured":"Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M et al (2015) Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol 72:1324\u20131333","DOI":"10.1001\/jamaneurol.2015.0607"},{"key":"705_CR37","doi-asserted-by":"crossref","unstructured":"Gillman KW, Starrett JE Jr, Parker MF, Xie K, Bronson JJ, Marcin LR et al (2010) Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable \u03b3-secretase inhibitor. ACS Med Chem Lett 1:120\u2013124","DOI":"10.1021\/ml1000239"},{"key":"705_CR38","doi-asserted-by":"crossref","unstructured":"Crump CJ, Castro SV, Wang F, Pozdnyakov N, Ballard TE, Sisodia SS et al (2012) BMS-708, 163 targets presenilin and lacks notch-sparing activity. Biochemistry 51:7209\u20137211","DOI":"10.1021\/bi301137h"},{"key":"705_CR39","doi-asserted-by":"crossref","unstructured":"Albright CF, Dockens RC, Meredith JE Jr, Olson RE, Slemmon R, Lentz KA et al (2013) Pharmacodynamics of selective inhibition of \u03b3-secretase by avagacestat. J Pharmacol Exp Ther 344:686\u2013695","DOI":"10.1124\/jpet.112.199356"},{"key":"705_CR40","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ayll\u00f3n MS, Campanari ML, Brinkmalm G, R\u00e1bano A, Alom J, Saura CA et al (2013) CSF presenilin-1 complexes are increased in Alzheimer\u2019s disease. Acta Neuropathol Commun 1:46","DOI":"10.1186\/2051-5960-1-46"},{"key":"705_CR41","doi-asserted-by":"crossref","unstructured":"Sogorb-Esteve A, Garc\u00eda-Ayll\u00f3n MS, Fortea J, S\u00e1nchez-Valle R, Lle\u00f3 A, Molinuevo JL, S\u00e1ez-Valero J (2016) Cerebrospinal fluid presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer\u2019s disease. Mol Neurodegener 11:66","DOI":"10.1186\/s13024-016-0131-2"},{"key":"705_CR42","doi-asserted-by":"crossref","unstructured":"Zahniser NR, Doolen S (2001) Chronic and acute regulation of Na+\/Cl\u2212-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol Ther 92:21\u201355","DOI":"10.1016\/S0163-7258(01)00158-9"},{"key":"705_CR43","doi-asserted-by":"crossref","unstructured":"Lauritzen I et al (2012) The \u03b2-secretase-derived C-terminal fragment of \u03b2APP, C99, but not A\u03b2, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci 32:16243\u201316255","DOI":"10.1523\/JNEUROSCI.2775-12.2012"},{"key":"705_CR44","doi-asserted-by":"crossref","unstructured":"Lauritzen I, Pardossi-Piquard R, Bauer C, Brigham E, Abraham JD, Ranaldi S et al (2016) Intraneuronal aggregation of the \u03b2-CTF fragment of APP (C99) induces A\u03b2-independent lysosomal-autophagic pathology. Acta Neuropathol 132:257\u2013276","DOI":"10.1007\/s00401-016-1577-6"},{"key":"705_CR45","doi-asserted-by":"crossref","unstructured":"Li J et al (2002) SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-beta peptide production. J Neurochem 82:1540\u20131548","DOI":"10.1046\/j.1471-4159.2002.01105.x"},{"key":"705_CR46","doi-asserted-by":"crossref","unstructured":"Massey LK, Mah AL, Monteiro MJ (2005) Ubiquilin regulates presenilin endoproteolysis and modulates gamma-secretase components, Pen-2 and nicastrin. Biochem J 391:513\u2013525","DOI":"10.1042\/BJ20050491"},{"key":"705_CR47","doi-asserted-by":"crossref","unstructured":"Chen F, Yang DS, Petanceska S, Yang A, Tandon A, Yu G et al (2000) Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J Biol Chem 275:36794\u201336802","DOI":"10.1074\/jbc.M006986200"},{"key":"705_CR48","doi-asserted-by":"crossref","unstructured":"Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK et al (2016) Restricted location of PSEN2\/\u03b3-secretase determines substrate specificity and generates an intracellular A\u03b2 pool. Cell 166:193\u2013208","DOI":"10.1016\/j.cell.2016.05.020"},{"key":"705_CR49","doi-asserted-by":"crossref","unstructured":"Mamada N, Tanokashira D, Hosaka A, Kametani F, Tamaoka A, Araki W (2015) Amyloid \u03b2-protein oligomers upregulate the \u03b2-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons. Mol Brain 8:73","DOI":"10.1186\/s13041-015-0163-5"},{"key":"705_CR50","doi-asserted-by":"crossref","unstructured":"Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR et al (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278:46107\u201346116","DOI":"10.1074\/jbc.M307757200"},{"key":"705_CR51","doi-asserted-by":"crossref","unstructured":"Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T et al (2004) Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876\u201312882","DOI":"10.1074\/jbc.M311652200"},{"key":"705_CR52","doi-asserted-by":"crossref","unstructured":"Wolfe MS (2012) \u03b3-Secretase as a target for Alzheimer\u2019s disease. Adv Pharmacol 64:127\u2013153","DOI":"10.1016\/B978-0-12-394816-8.00004-0"},{"key":"705_CR53","doi-asserted-by":"crossref","unstructured":"Wakabayashi T, De Strooper B (2008) Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 23:194\u2013204","DOI":"10.1152\/physiol.00009.2008"},{"key":"705_CR54","doi-asserted-by":"crossref","unstructured":"Lle\u00f3 A, Saura CA (2011) \u03b3-secretase substrates and their implications for drug development in Alzheimer\u2019s disease. Curr Top Med Chem 11:1513\u20131527","DOI":"10.2174\/156802611795861004"},{"key":"705_CR55","doi-asserted-by":"crossref","unstructured":"Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X et al (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide\u00a0inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer\u2019s disease. J Pharmacol Exp Ther 331:598\u20136087","DOI":"10.1124\/jpet.109.152975"},{"key":"705_CR56","doi-asserted-by":"crossref","unstructured":"De Strooper B, Ch\u00e1vez-Guti\u00e9rrez L (2015) Learning by failing: ideas and concepts to tackle \u03b3-secretases in Alzheimer\u2019s disease and beyond. Annu Rev Pharmacol Toxicol 55:419\u2013437","DOI":"10.1146\/annurev-pharmtox-010814-124309"},{"key":"705_CR57","doi-asserted-by":"crossref","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369:341\u2013350","DOI":"10.1056\/NEJMoa1210951"},{"key":"705_CR58","doi-asserted-by":"crossref","unstructured":"Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y et al (2012) Differential effects between \u03b3-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 32:2037\u20132050","DOI":"10.1523\/JNEUROSCI.4264-11.2012"},{"key":"705_CR59","doi-asserted-by":"crossref","unstructured":"Frisoni GB, Rozzini L, Gozzetti A, Binetti G, Zanetti O, Bianchetti A et al (1999) Behavioral syndromes in Alzheimer\u2019s disease: description and correlates. Dement Geriatr Cogn Disord 10:130\u2013138","DOI":"10.1159\/000017113"},{"key":"705_CR60","doi-asserted-by":"crossref","unstructured":"Chung JA, Cummings JL (2000) Neurobehavioral and neuropsychiatric symptoms in Alzheimer\u2019s disease. Neurol Clin 18:829\u2013846","DOI":"10.1016\/S0733-8619(05)70228-0"},{"key":"705_CR61","doi-asserted-by":"crossref","unstructured":"Yan L, Li L, Han W, Pan B, Xue X, Mei B (2013) Age-related neuropsychiatric symptoms in presenilins conditional double knockout mice. Brain Res Bull 97:104\u2013111","DOI":"10.1016\/j.brainresbull.2013.06.002"},{"key":"705_CR62","doi-asserted-by":"crossref","unstructured":"Lalonde R, Qian S, Strazielle C (2003) Transgenic mice expressing the PS1-A246E mutation: effects on spatial learning, exploration, anxiety, and motor coordination. Behav Brain Res 138:71\u201379","DOI":"10.1016\/S0166-4328(02)00230-9"},{"key":"705_CR63","doi-asserted-by":"crossref","unstructured":"Yuk DY, Lee YK, Nam SY, Yun YW, Hwang DY, Choi DY et al (2009) Reduced anxiety in the mice expressing mutant (N141I) presenilin 2. J Neurosci Res 87:522\u2013531","DOI":"10.1002\/jnr.21861"},{"key":"705_CR64","doi-asserted-by":"crossref","unstructured":"Luciano M, Houlihan LM, Harris SE, Gow AJ, Hayward C, Starr JM et al (2010) Association of existing and new candidate genes for anxiety, depression and personality traits in older people. Behav Genet 40:518\u2013532","DOI":"10.1007\/s10519-009-9326-4"},{"key":"705_CR65","doi-asserted-by":"crossref","unstructured":"Borghys H, Tuefferd M, Van Broeck B, Clessens E, Dillen L, Cools W et al (2012) A canine model to evaluate efficacy and safety of \u03b3-secretase inhibitors and modulators. J Alzheimers Dis 28:809\u2013822","DOI":"10.3233\/JAD-2011-111475"},{"key":"705_CR66","doi-asserted-by":"crossref","unstructured":"Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD et al (2010) Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 30:6743\u20136750","DOI":"10.1523\/JNEUROSCI.1381-10.2010"},{"key":"705_CR67","doi-asserted-by":"crossref","unstructured":"Lle\u00f3 A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N et al (2015) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 11:41\u201355","DOI":"10.1038\/nrneurol.2014.232"},{"key":"705_CR68","doi-asserted-by":"crossref","unstructured":"Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R et al (2012) Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid A\u03b2 levels in healthy young men. Clin Drug Investig 32:761\u2013769","DOI":"10.1007\/s40261-012-0006-4"},{"key":"705_CR69","doi-asserted-by":"crossref","unstructured":"Dockens R, Wang JS, Castaneda L, Sverdlov O, Huang SP, Slemmon R et al (2012) A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet 51:681\u2013693","DOI":"10.1007\/s40262-012-0005-x"},{"key":"705_CR70","doi-asserted-by":"crossref","unstructured":"Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR et al (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 30:317\u2013325","DOI":"10.1097\/WNF.0b013e31805b7660"},{"key":"705_CR71","doi-asserted-by":"crossref","unstructured":"Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC et al (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66:48\u201354","DOI":"10.1002\/ana.21623"},{"key":"705_CR72","doi-asserted-by":"crossref","unstructured":"Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA et al (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031\u20131038","DOI":"10.1001\/archneur.65.8.1031"},{"key":"705_CR73","doi-asserted-by":"crossref","unstructured":"Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E et al (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer\u2019s disease. Alzheimers Res Ther 2:7","DOI":"10.1186\/alzrt30"},{"key":"705_CR74","doi-asserted-by":"crossref","unstructured":"Svedru\u017ei\u0107 \u017dM, Popovi\u0107 K, \u0160endula-Jengi\u0107 V (2013) Modulators of \u03b3-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer\u2019s disease. PLoS One 8:e50759","DOI":"10.1371\/journal.pone.0050759"},{"key":"705_CR75","doi-asserted-by":"crossref","unstructured":"Pitsi D, Octave JN (2004) Presenilin 1 stabilizes the C-terminal fragment of the amyloid precursor protein independently of gamma-secretase activity. J Biol Chem 279:25333\u201325338","DOI":"10.1074\/jbc.M312710200"},{"key":"705_CR76","doi-asserted-by":"crossref","unstructured":"De Strooper B, Iwatsubo T, Wolfe MS (2012) Presenilins and \u03b3-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006304","DOI":"10.1101\/cshperspect.a006304"},{"key":"705_CR77","doi-asserted-by":"crossref","unstructured":"Stiller I, Liz\u00e1k B, B\u00e1nhegyi G (2014) Physiological functions of presenilins; beyond \u03b3-secretase. Curr Pharm Biotechnol 15:1019\u20131025","DOI":"10.2174\/1389201015666141122204139"},{"key":"705_CR78","doi-asserted-by":"crossref","unstructured":"Leem JY, Vijayan S, Han P, Cai D, Machura M, Lopes KO et al (2002) Presenilin 1 is required for maturation and cell surface accumulation of nicastrin. J Biol Chem 277:19236\u201319240","DOI":"10.1074\/jbc.C200148200"},{"key":"705_CR79","doi-asserted-by":"crossref","unstructured":"H\u00e9bert SS, Bourdages V, Godin C, Ferland M, Carreau M, L\u00e9vesque G (2003) Presenilin-1 interacts directly with the beta-site amyloid protein precursor cleaving enzyme (BACE1). Neurobiol Dis 13:238\u2013245","DOI":"10.1016\/S0969-9961(03)00035-4"},{"key":"705_CR80","doi-asserted-by":"crossref","unstructured":"Silveyra MX, Evin G, Montenegro MF, Vidal CJ, Mart\u00ednez S, Culvenor JG (2008) Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation. Mol Cell Biol 28:2908\u20132919","DOI":"10.1128\/MCB.02065-07"},{"key":"705_CR81","doi-asserted-by":"crossref","unstructured":"Leem JY, Saura CA, Pietrzik C, Christianson J, Wanamaker C, King LT (2002) A role for presenilin 1 in regulating the delivery of amyloid precursor protein to the cell surface. Neurobiol Dis 11:64\u201382","DOI":"10.1006\/nbdi.2002.0546"},{"key":"705_CR82","doi-asserted-by":"crossref","unstructured":"Farquhar MJ, Gray CW, Breen KC (2003) The over-expression of the wild type or mutant forms of the presenilin-1 protein alters glycoprotein processing in a human neuroblastoma cell line. Neurosci Lett 346:53\u201356","DOI":"10.1016\/S0304-3940(03)00544-5"},{"key":"705_CR83","doi-asserted-by":"crossref","unstructured":"De Strooper B (2014) Lessons from a failed \u03b3-secretase Alzheimer trial. Cell 159:721\u2013726","DOI":"10.1016\/j.cell.2014.10.016"},{"key":"705_CR84","doi-asserted-by":"crossref","unstructured":"Xia W, Wong ST, Hanlon E, Morin P (2012) \u03b3-Secretase modulator in Alzheimer\u2019s disease: shifting the end. J Alzheimers Dis 31:685\u2013696","DOI":"10.3233\/JAD-2012-120751"},{"key":"705_CR85","doi-asserted-by":"crossref","unstructured":"Yan R, Vassar R (2014) Targeting the \u03b2 secretase BACE1 for Alzheimer\u2019s disease therapy. Lancet Neurol 13:319\u2013329","DOI":"10.1016\/S1474-4422(13)70276-X"},{"key":"705_CR86","doi-asserted-by":"crossref","unstructured":"Lahiri DK, Maloney B, Long JM, Greig NH (2014) Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement 10:S411\u2013S419","DOI":"10.1016\/j.jalz.2013.11.004"},{"key":"705_CR87","doi-asserted-by":"crossref","unstructured":"Gertsik N, Chiu D, Li YM (2015) Complex regulation of \u03b3-secretase: from obligatory to modulatory subunits. Front Aging Neurosci 6:342","DOI":"10.3389\/fnagi.2014.00342"},{"key":"705_CR88","doi-asserted-by":"crossref","unstructured":"Naoko Takebe, Dat Nguyen, Sherry X. Yang, (2014) Targeting Notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol Ther 141(2):140\u2013149","DOI":"10.1016\/j.pharmthera.2013.09.005"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-017-0705-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-017-0705-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-017-0705-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T08:40:23Z","timestamp":1570005623000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-017-0705-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,16]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1007\/s12035-017-0705-1","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,16]]}}}